Premium
Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables
Author(s) -
Barnard Nicola J.,
Hall P. A.,
Lemoine N. R.,
Kadar N.
Publication year - 1987
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.1711520407
Subject(s) - pathological , immunostaining , mitotic index , breast carcinoma , proliferation index , pathology , ki 67 , carcinoma , correlation , mammary gland , carcinoma in situ , breast cancer , immunohistochemistry , medicine , biology , cancer , mitosis , geometry , mathematics , microbiology and biotechnology
Abstract Sixty cases of primary breast carcinoma have been studied using a monoclonal antibody, Ki67, which recognizes an antigen expressed by cells in G1, S, G2, and M phases of the cell cycle but not Go. A Ki67 score (positive cells/total tumour cells) was determined, and possible relationships between this index of cellular proliferation and a number of clinical and pathological parameters were investigated. There was a strong positive correlation between the Ki67 score and mitotic index ( p < 0.001), a weak negative correlation with age ( p < 0.02), and weak positive correlations with histological tumour grade ( p < 0.03), tumour necrosis ( p < 0.01), and cellular reaction ( p < 0.01). No relationship was noted between the Ki67 score and tumour size, nodal status, tumour oestrogen receptor levels, or menopausal status. The Ki67 score may prove to be an objective indicator of biological behaviour and thus be of clinical significance, particularly since it is not strongly related to other clinical and pathological parameters used in predicting outcome in breast carcinoma.